MELANOMA STAGE III

This study is testing a new type of targeted radiation drug called [212Pb]VMT01 for people with advanced melanoma that has returned or spread and has not responded to other treatments. The drug is designed to deliver a powerful dose of radiation directly to melanoma cells. Resear…

This study is testing whether giving immunotherapy drugs before surgery can lead to better outcomes for people with advanced melanoma that has spread to nearby lymph nodes or tissue. The treatment aims to help the patient's own immune system attack the cancer to shrink tumors pri…

This study is testing whether adding a low-dose chemotherapy drug (cyclophosphamide) to an existing immunotherapy (pembrolizumab) can help patients with advanced melanoma that has stopped responding to standard treatments. The trial will enroll 14 adults with stage III or IV mela…

This study is testing a combination of three immunotherapy drugs (Interleukin-2, ipilimumab, and nivolumab) for people with advanced, inoperable melanoma that has continued to grow despite prior immunotherapy. The goal is to see if this specific sequence and combination can bette…

This study is testing whether adding an oral supplement called beta-glucan to the immunotherapy drug pembrolizumab can improve the immune system's response against melanoma. It involves 30 adults with stage III or IV melanoma who have no active disease but are receiving pembroliz…

This study aims to monitor the long-term safety and effectiveness of Miltenyi's CAR T cell therapies in patients who were treated at least a year ago. It will follow 40 patients with various cancers, including lymphoma, leukemia, and melanoma, to check for any late side effects a…

This study is testing whether taking two pills, binimetinib and imatinib, can help control advanced melanoma that has a specific genetic change called a KIT mutation. The trial is for up to 25 adults whose cancer has spread or cannot be removed by surgery and who have already tri…

This study tests whether treatment decisions for advanced melanoma can be personalized based on how well tumors respond to drug therapy before surgery. Patients with specific genetic mutations receive targeted drugs before surgery, then get different follow-up treatments dependin…

This study aims to learn if a special scan (PET/CT) and a blood test for tumor DNA can help doctors predict, very early on, which patients with advanced melanoma will respond well to immunotherapy and which might experience side effects. It will enroll 24 patients who are startin…